MOG.to 1.58 -.02 MonoGen, "Cardinal Health, Inc. (NYSE: CAH) will market, sell and distribute MonoGen Inc.'s advanced new automation technology for diagnostic laboratories."
Jan 17, 2007 (M2 PRESSWIRE via COMTEX News Network) --
Please visit www.Streetinvesting.com for the full report.
Although Bay Street exhibited a decline after a three-day stretch of success Tuesday, investors of MonoGen Inc. (TSX:MOG) were able to secure a positive return amidst a sea of red. Come the toll of the day's closing bell, the company's shareholders experienced an 18.80% up-tick accompanied by a trading volume of 808,204.
The Resource sector saw a significant sell-off at the start of 2007. Although this may have been bad for some investors, others continued to see improvement. One group of prospective companies that continues to be of particular interest to both traders, analysts, and our researcher's recently are our beloved Bio-Tech's.
Recently, our experienced team of researchers has been placing an increased focus on Bio-Tech's, as well as companies involved with the distribution or production of pharmaceutical or medical wares. MonoGen Inc. was one of the prospective companies which we have chosen to bring to your attention.
MonoGen, Inc. of Vernon Hills, Illinois, is a privately held corporation focused on providing products that automate anatomic and molecular pathology laboratories, particularly the process of preparing and analyzing cellular specimens. MonoGen's products have been designed not only to improve cytology test preparations and analyses, but also to serve as a universal platform for more sensitive and effective tests for non-gynecological cancers. MonoGen's intrinsic value is protected by a broad-patent portfolio in specimen preparation, molecular diagnostics, and imaging and information systems.
As we have mentioned to our members time and time again, we feel biotech stocks are the, "Wave of the future."
In some of the most recent news to surface surrounding the aforementioned MonoGen Inc., which we feel may have had an effect on the day's success in the marketplace, as well as an ongoing effect on shareholder outcome, Under a newly signed distribution agreement, Cardinal Health, Inc. (NYSE: CAH) will market, sell and distribute MonoGen Inc.'s advanced new automation technology for diagnostic laboratories. The MonoGen system automates the preparation of patient specimens for cell-based diagnosis. The agreement gives Cardinal Health exclusive rights to distribute MonoGen's proprietary pathology products in the United States. Financial terms were not disclosed.
The companies are launching the new specimen-preparation system, called MonoPrep(R), this week in Chicago at the 52nd annual scientific meeting of the American Society of Cytopathology. The meeting is being held November 12 through November 17 at the Sheraton Chicago Hotel and Towers.
The MonoPrep system is...To continue with the full report, more information and research please go to www.streetinvesting.com
Please visit www.streetinvesting.com for a complimentary subscription to access this issuance and other related in-depth articles. Please note that membership does not require credit card information nor does it require a commitment to our service.
We have initiated this news release as a tool to keep investors informed about the market. The information contained herein comes from an unbiased perspective and we do not have a vested interest in the companies mentioned in this release. Becoming a member to www.streetinvesting.com will give you access to all the on-going information and investment news that we come across.
Investors wishing to seek a different approach to their investment theories and concepts and to be informed of unique investment opportunities should also visit www.streetinvesting.com for a free membership. |
